Cannabinoid Receptor-2 Ameliorates Inflammation in Murine Model of Crohn’s Disease
Authors:
Open Access
- 17 July 2017
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 11 (11) , 1369-1380
Abstract
Cannabinoid receptor stimulation may have positive symptomatic effects on inflammatory bowel disease [IBD] patients through analgesic and anti-inflammatory effects. The cannabinoid 2 receptor [CB2R] is expressed primarily on immune cells, including CD4+ T cells, and is induced by active inflammation in both humans and mice. We therefore investigated the effect of targeting CB2R in a preclinical IBD model. Employing a chronic ileitis model [TNFΔARE/+ mice], we assessed expression of the CB2R receptor in ileal tissue and on CD4+ T cells and evaluated the effect of stimulation with CB2R-selective ligand GP-1a both in vitro and in vivo. Additionally, we compared cannabinoid receptor expression in the ilea and colons of healthy human controls with that of Crohn’s disease patients. Ileal expression of CB2R and the endocannabinoid anandamide [AEA] was increased in actively inflamed TNF∆ARE/+ mice compared with controls. CB2R mRNA was preferentially induced on regulatory T cells [Tregs] compared with T effector cells, approximately 2.4-fold in wild-type [WT] and 11-fold in TNF∆ARE/+ mice. Furthermore, GP-1a enhanced Treg suppressive function with a concomitant increase in IL-10 secretion. GP-1a attenuated murine ileitis, as demonstrated by improved histological scoring and decreased inflammatory cytokine expression. Lastly, CB2R is downregulated in both chronically inflamed TNF∆ARE/+ mice and in IBD patients. In summary, the endocannabinoid system is induced in murine ileitis but is downregulated in chronic murine and human intestinal inflammation, and CB2R activation attenuates murine ileitis, establishing an anti-inflammatory role of the endocannabinoid system.Keywords
Funding Information
- National Institutes of Health (2T32DK067009-11)
- National Institute on Aging
This publication has 52 references indexed in Scilit:
- The cannabinoid TRPA1 agonist cannabichromene inhibits nitric oxide production in macrophages and ameliorates murine colitisBritish Journal of Pharmacology, 2013
- Flt3 ligand expands CD103 + dendritic cells and FoxP3 + T regulatory cells, and attenuates Crohn's-like murine ileitisGut, 2011
- Retinoic Acid Attenuates Ileitis by Restoring the Balance Between T-Helper 17 and T Regulatory CellsGastroenterology, 2011
- Impact of fusion to Gαi2 and co-expression with RGS proteins on pharmacological properties of human cannabinoid receptors CB1R and CB2RJournal of Pharmacy and Pharmacology, 2011
- Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone (SAB378), a Peripherally Restricted Cannabinoid CB1/CB2 Receptor Agonist, Inhibits Gastrointestinal Motility but Has No Effect on Experimental Colitis in MiceThe Journal of Pharmacology and Experimental Therapeutics, 2010
- Emerging role of the cannabinoid receptor CB2in immune regulation: therapeutic prospects for neuroinflammationExpert Reviews in Molecular Medicine, 2009
- Cannabinoid CB2receptors: a therapeutic target for the treatment of inflammatory and neuropathic painBritish Journal of Pharmacology, 2008
- Defective regulatory and effector T cell functions in patients with FOXP3 mutationsJournal of Clinical Investigation, 2006
- Inhibition of an equilibrative nucleoside transporter by cannabidiol: A mechanism of cannabinoid immunosuppressionProceedings of the National Academy of Sciences, 2006
- Maintenance infliximab for Crohn's disease: the ACCENT I randomised trialThe Lancet, 2002